TargetGlutathione S-transferase P/Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D](Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 1nMpH: 7.5 T: 2°CAssay Description:A recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accession n...More data for this Ligand-Target Pair
TargetDual specificity mitogen-activated protein kinase kinase 1(Homo sapiens (Human))
Bayer Healthcare
Curated by ChEMBL
Bayer Healthcare
Curated by ChEMBL
Affinity DataIC50: 1.80nMAssay Description:Inhibition of MEK1 in human HeLa-MaTu matched pair cells assessed as reduction in ERK phosphorylationMore data for this Ligand-Target Pair
TargetGlutathione S-transferase P/Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D](Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 2.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 2.58nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 2.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 2.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetGlutathione S-transferase P/Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D](Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:A recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accession n...More data for this Ligand-Target Pair
TargetGlutathione S-transferase P/Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D](Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:A recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accession n...More data for this Ligand-Target Pair
TargetGlutathione S-transferase P/Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D](Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:A recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accession n...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.30nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.30nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.35nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.45nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.55nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.90nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 3.96nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetGlutathione S-transferase P/Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D](Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:A recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accession n...More data for this Ligand-Target Pair
TargetGlutathione S-transferase P/Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D](Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:A recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accession n...More data for this Ligand-Target Pair
TargetGlutathione S-transferase P/Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D](Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:A recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accession n...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.04nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.23nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.38nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.40nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.49nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.5nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.52nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.60nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.61nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.70nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.70nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.80nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.80nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 4.91nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetGlutathione S-transferase P/Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D](Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetGlutathione S-transferase P/Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D](Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:A recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accession n...More data for this Ligand-Target Pair
TargetGlutathione S-transferase P/Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D](Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:A recombinant fusion protein of Glutathione-S-Transferase (GST, N-terminally) and human full-length MKNK1 (amino acids 1-424 and T344D of accession n...More data for this Ligand-Target Pair
TargetGlutathione S-transferase P/Isoform 2 of MAP kinase-interacting serine/threonine-protein kinase 1 (MNK1a) [T344D](Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:MKNK1-inhibitory activity at high ATP of compounds of the present invention after their preincubation with MKNK1 was quantified employing the TR-FRET...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5.03nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5.03nMAssay Description:Bub1-inhibitory activities of compounds described in the present invention were quantified using a time-resolved fluorescence energy transfer (TR-FRE...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5.04nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5.05nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair
TargetMitotic checkpoint serine/threonine-protein kinase BUB1(Homo sapiens (Human))
Bayer Intellectual Property
US Patent
Bayer Intellectual Property
US Patent
Affinity DataIC50: 5.09nMAssay Description:In a typical assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 μM, 0.51 μM, 1.7 μ...More data for this Ligand-Target Pair